{"id":935009,"date":"2026-02-06T16:04:19","date_gmt":"2026-02-06T21:04:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"},"modified":"2026-02-06T16:04:19","modified_gmt":"2026-02-06T21:04:19","slug":"newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","title":{"rendered":"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NAARDEN, The Netherlands and MIAMI, Feb.  06, 2026  (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam\u2019s Board of Directors approved the grant of inducement share options covering an aggregate of 217,000 of NewAmsterdam\u2019s ordinary shares to four (4) non-executive new hires. The share options were granted as an inducement material to the employees\u2019 acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the \u201c2024 Inducement Plan\u201d) and in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>The share options have an exercise price per share equal to $31.57, which represents the closing market price on the Nasdaq Stock Market of the Company\u2019s ordinary shares on February 2, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee\u2019s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.<\/p>\n<p>\n        <strong>About NewAmsterdam<\/strong><br \/>\n        <br \/>NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.<\/p>\n<p>\n        <strong>Company Contact<\/strong><br \/>\n        <br \/>Matthew Philippe<br \/>P: 1-917-882-7512<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p6JY1cGFZBz_0-IUE02MJPwe2SZhExQri3-I6ZSLZ2pFlouj1Ai2ovxYzMVjRbYp8PfxJ3etziMJUMj01fgX7gURORs-higjn_XvUMVOcSYgFVoVlfhRnP51pQePWPEodtWrPWe94q_kboWo9hlytw==\" rel=\"nofollow\" target=\"_blank\">matthew.philippe@newamsterdampharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDM5MiM3NDEzNTU4IzIyNTAzNDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmFiMWMyNmEtZmM0NS00YTU1LWI5N2EtYWEzZTkzMmNiMWMxLTEyNjE4OTQtMjAyNi0wMi0wNi1lbg==\/tiny\/NewAmsterdam-Pharma-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam\u2019s Board of Directors approved the grant of inducement share options covering an aggregate of 217,000 of NewAmsterdam\u2019s ordinary shares to four (4) non-executive new hires. The share options were granted as an inducement material to the employees\u2019 acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the \u201c2024 Inducement Plan\u201d) and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-935009","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam\u2019s Board of Directors approved the grant of inducement share options covering an aggregate of 217,000 of NewAmsterdam\u2019s ordinary shares to four (4) non-executive new hires. The share options were granted as an inducement material to the employees\u2019 acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the \u201c2024 Inducement Plan\u201d) and &hellip; Continue reading &quot;NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T21:04:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDM5MiM3NDEzNTU4IzIyNTAzNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-02-06T21:04:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\"},\"wordCount\":365,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MDM5MiM3NDEzNTU4IzIyNTAzNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\",\"name\":\"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MDM5MiM3NDEzNTU4IzIyNTAzNDE=\",\"datePublished\":\"2026-02-06T21:04:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MDM5MiM3NDEzNTU4IzIyNTAzNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MDM5MiM3NDEzNTU4IzIyNTAzNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","og_locale":"en_US","og_type":"article","og_title":"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam\u2019s Board of Directors approved the grant of inducement share options covering an aggregate of 217,000 of NewAmsterdam\u2019s ordinary shares to four (4) non-executive new hires. The share options were granted as an inducement material to the employees\u2019 acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the \u201c2024 Inducement Plan\u201d) and &hellip; Continue reading \"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-06T21:04:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDM5MiM3NDEzNTU4IzIyNTAzNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-02-06T21:04:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"},"wordCount":365,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDM5MiM3NDEzNTU4IzIyNTAzNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","name":"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDM5MiM3NDEzNTU4IzIyNTAzNDE=","datePublished":"2026-02-06T21:04:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDM5MiM3NDEzNTU4IzIyNTAzNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDM5MiM3NDEzNTU4IzIyNTAzNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=935009"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935009\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=935009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=935009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=935009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}